Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Oral eflornithine for African sleeping sickness

Late-stage African sleeping sickness (HAT - human African trypanosomiasis) is fatal unless treated. Only two drugs are available, melarsoprol and eflornithine, both requiring intravenous administration. The former is toxic with diminishing clinical efficacy. If an oral treatment with eflornithine can be developed, many more patients can be cured.

This project will provide knowledge on the disposition of eflornithine in the body to support its use for oral treatment. Investigations will focus on the possible differential intestinal uptake, and/or brain penetration of its two stereoisomers. The most potent isomer seems to exhibit low, saturable oral absorption and low penetration to the brain (site of action). The mechanisms for eflornithine permeability/transport across biological membranes are investigated in a sequence of in vitro - in vivo studies aiming to understand which factors may be limiting to oral eflornithine treatment.

WHO: Human African trypanosomiasis >>>

Contact Information

Michael Ashton

Box 431 , 405 30 Göteborg

Visiting Address:
Medicinaregatan 13A

Phone:
+46 (0)31 786 34 12

Fax:
+46 (0)31 786 32 84

Page Manager: Webbredaktör|Last update: 9/10/2019
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?